End-to-End Cell Therapy Automation: An Immunotherapy Case Study

September 15, 2017

Yaling Shi

Yaling Shi is senior manager R&T, Lonza Inc.

, James B Morrissey

James B Morrissey

James B Morrissey is bioengineering scientist-Cocoon Program, Octane Biotech Inc.

, Nuala Trainor

Nuala Trainor

Nuala Trainor is director of Biological Programs, Octane Biotech Inc.

BioPharm International, BioPharm International-09-15-2017, Volume 2017 eBook, Issue 2

Pages: 10–18

Consider automation early in the rollout of clinical translation and scale up of clinical-trial protocols.

As anticipation builds about accelerated clinical adoption of advanced cell therapies, more attention is turning to the underlying manufacturing strategies that will allow these therapies to benefit patients worldwide. While cell therapies hold great promise clinically, high manufacturing costs relative to reimbursement present a formidable roadblock to commercialization. Therefore, the need for cost effectiveness, process efficiency, and product consistency is driving efforts for automation in numerous cell therapy fields and particularly for T-cell immunotherapies.

Download the

Article Details

BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 10–18

Citation

When referring to this article, please cite it as J. Morrissey, N. Trainor, and Y. Shi, "End-to-End Cell Therapy Automation: An Immunotherapy Case Study," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).